Build Your Comparison

Side-by-side financial analysis
TOI logo
TOI
OPCH logo
OPCH
MCK logo
MCK
CAH logo
CAH
CVS logo
CVS
KO logo
KO
Try popular comparisons:

Stock Comparison

TOI vs OPCH vs MCK vs CAH vs CVS vs KO

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
TOI
The Oncology Institute, Inc.

Medical - Care Facilities

HealthcareNASDAQ • US
Market Cap$5.41B
5Y Perf.-47.2%
OPCH
Option Care Health, Inc.

Medical - Care Facilities

HealthcareNASDAQ • US
Market Cap$3.25B
5Y Perf.+49.6%
MCK
McKesson Corporation

Medical - Distribution

HealthcareNYSE • US
Market Cap$94.25B
5Y Perf.+411.0%
CAH
Cardinal Health, Inc.

Medical - Distribution

HealthcareNYSE • US
Market Cap$52.68B
5Y Perf.+328.9%
CVS
CVS Health Corporation

Medical - Healthcare Plans

HealthcareNYSE • US
Market Cap$130.09B
5Y Perf.+56.9%
KO
The Coca-Cola Company

Beverages - Non-Alcoholic

Consumer DefensiveNYSE • US
Market Cap$355.61B
5Y Perf.+84.9%

TOI vs OPCH vs MCK vs CAH vs CVS vs KO — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
TOI logoTOI
OPCH logoOPCH
MCK logoMCK
CAH logoCAH
CVS logoCVS
KO logoKO
IndustryMedical - Care FacilitiesMedical - Care FacilitiesMedical - DistributionMedical - DistributionMedical - Healthcare PlansBeverages - Non-Alcoholic
Market Cap$5.41B$3.25B$94.25B$52.68B$130.09B$355.61B
Revenue (TTM)$546M$5.67B$403.43B$250.55B$407.90B$49.28B
Net Income (TTM)$-44M$206M$4.76B$1.56B$2.93B$13.70B
Gross Margin14.8%18.0%3.6%3.7%13.9%61.7%
Operating Margin-6.0%5.9%1.6%0.9%1.5%29.3%
Forward P/E11.3x17.7x20.8x13.8x25.3x
Total Debt$104M$0.00$8.61B$9.35B$93.59B$45.49B
Cash & Equiv.$34M$233M$3.98B$3.87B$8.51B$10.27B

TOI vs OPCH vs MCK vs CAH vs CVS vs KOLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

TOI
OPCH
MCK
CAH
CVS
KO
StockJun 20Jun 26Return
The Oncology Instit… (TOI)10052.8-47.2%
Option Care Health,… (OPCH)100149.6+49.6%
McKesson Corporation (MCK)100511.0+411.0%
Cardinal Health, In… (CAH)100428.9+328.9%
CVS Health Corporat… (CVS)100156.9+56.9%
The Coca-Cola Compa… (KO)100184.9+84.9%

Price return only. Dividends and distributions are not included.

Quick Verdict: TOI vs OPCH vs MCK vs CAH vs CVS vs KO

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: TOI and CVS are tied at the top with 2 categories each (6-stock set) — the right choice depends on your priorities. CVS Health Corporation is the stronger pick specifically for capital preservation and lower volatility and dividend income and shareholder returns. KO and OPCH also each lead in at least one category. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
TOI
The Oncology Institute, Inc.
The Growth Play

TOI has the current edge in this matchup, primarily because of its strength in growth exposure.

  • Rev growth 27.8%, EPS growth 23.9%, 3Y rev CAGR 25.8%
  • 27.8% revenue growth vs CAH's -1.9%
  • +100.4% vs OPCH's -34.9%
Best for: growth exposure
OPCH
Option Care Health, Inc.
The Value Play

OPCH is the clearest fit if your priority is value.

  • Lower P/E (11.3x vs 25.3x)
Best for: value
MCK
McKesson Corporation
The Long-Run Compounder

MCK is the clearest fit if your priority is long-term compounding.

  • 337.8% 10Y total return vs CAH's 211.1%
Best for: long-term compounding
CAH
Cardinal Health, Inc.
The Lower-Volatility Pick

CAH doesn't hold a clear category lead here; it's more of a secondary option in this specific comparison.

Best for: healthcare exposure
CVS
CVS Health Corporation
The Insurance Pick

CVS is the #2 pick in this set and the best alternative if income & stability and sleep-well-at-night is your priority.

  • Dividend streak 0 yrs, beta 0.19, yield 2.6%
  • Lower volatility, beta 0.19, current ratio 0.84x
  • Beta 0.19, yield 2.6%, current ratio 0.84x
  • Beta 0.19 vs TOI's 1.95
Best for: income & stability and sleep-well-at-night
KO
The Coca-Cola Company
The Quality Compounder

KO ranks third and is worth considering specifically for quality and efficiency.

  • 27.8% margin vs TOI's -8.0%
  • 13.1% ROA vs TOI's -26.5%, ROIC 15.8% vs -41.2%
Best for: quality and efficiency
See the full category breakdown
CategoryWinnerWhy
GrowthTOI logoTOI27.8% revenue growth vs CAH's -1.9%
ValueOPCH logoOPCHLower P/E (11.3x vs 25.3x)
Quality / MarginsKO logoKO27.8% margin vs TOI's -8.0%
Stability / SafetyCVS logoCVSBeta 0.19 vs TOI's 1.95
DividendsCVS logoCVS2.6% yield, vs KO's 2.5%, (2 stocks pay no dividend)
Momentum (1Y)TOI logoTOI+100.4% vs OPCH's -34.9%
Efficiency (ROA)KO logoKO13.1% ROA vs TOI's -26.5%, ROIC 15.8% vs -41.2%

TOI vs OPCH vs MCK vs CAH vs CVS vs KO — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

Discover the Biotech & Healthcare Stocks Theme

These companies are key players in the Biotech & Healthcare Stocks ecosystem. See how they stack up against the rest of the sector.

Explore Theme
TOIThe Oncology Institute, Inc.
FY 2025
Health Care, Patient Service
49.5%$229M
Fee For Service
32.1%$149M
Capitated Revenue
17.4%$80M
Clinical Research Trials And Other Revenue
1.0%$5M
OPCHOption Care Health, Inc.
FY 2025
Reportable Segment
100.0%$5.6B
MCKMcKesson Corporation
FY 2026
North American Pharmaceutical Segment
83.4%$336.7B
Oncology And Multispecialty Segment
12.0%$48.4B
Medical-Surgical Solutions Segment
2.9%$11.5B
Prescription Technology Solutions Segment
1.4%$5.8B
Segment Reporting, Reconciling Item, Excluding Corporate Nonsegment
0.3%$1.0B
CAHCardinal Health, Inc.
FY 2025
Pharmaceutical Member
91.9%$204.6B
GMPD
5.7%$12.6B
Other Operating Segment
2.4%$5.4B
CVSCVS Health Corporation
FY 2025
Pharmacy Revenue
58.9%$229.0B
Premiums
34.6%$134.8B
Front Store Revenue
5.5%$21.5B
Product and Service, Other
1.0%$3.9B
KOThe Coca-Cola Company
FY 2025
Pacific
84.6%$31.6B
Bottling investments
15.4%$5.7B

TOI vs OPCH vs MCK vs CAH vs CVS vs KO — Financial Metrics

Side-by-side numbers across 6 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLTOILAGGINGCVS

Who Leads Where

KO leads in 1 of 6 categories

OPCH leads 1 • TOI leads 1 • MCK leads 0 • CAH leads 0 • CVS leads 0 • 3 tied

Explore the data ↓
CVSCVS Health Corporation
0leads
CAHCardinal Health, Inc.
0leads
MCKMcKesson Corporation
0leads
KOThe Coca-Cola Company
1leads
OPCHOption Care Health, I…
1leads
TOIThe Oncology Institut…
1leads
6 Total Categories

Income & Cash Flow (Last 12 Months)

KO leads this category, winning 4 of 6 comparable metrics.

CVS is the larger business by revenue, generating $407.9B annually — 747.4x TOI's $546M. KO is the more profitable business, keeping 27.8% of every revenue dollar as net income compared to TOI's -8.0%. On growth, TOI holds the edge at +41.2% YoY revenue growth, suggesting stronger near-term business momentum.

MetricTOI logoTOIThe Oncology Inst…OPCH logoOPCHOption Care Healt…MCK logoMCKMcKesson Corporat…CAH logoCAHCardinal Health, …CVS logoCVSCVS Health Corpor…KO logoKOThe Coca-Cola Com…
RevenueTrailing 12 months$546M$5.7B$403.4B$250.5B$407.9B$49.3B
EBITDAEarnings before interest/tax-$26M$406M$7.1B$3.2B$10.5B$15.5B
Net IncomeAfter-tax profit-$44M$206M$4.8B$1.6B$2.9B$13.7B
Free Cash FlowCash after capex-$26M$244M$5.9B$4.4B$7.4B$12.6B
Gross MarginGross profit ÷ Revenue+14.8%+18.0%+3.6%+3.7%+13.9%+61.7%
Operating MarginEBIT ÷ Revenue-6.0%+5.9%+1.6%+0.9%+1.5%+29.3%
Net MarginNet income ÷ Revenue-8.0%+3.6%+1.2%+0.6%+0.7%+27.8%
FCF MarginFCF ÷ Revenue-4.7%+4.3%+1.5%+1.8%+1.8%+25.5%
Rev. Growth (YoY)Latest quarter vs prior year+41.2%+1.3%+6.0%+11.0%+6.2%+12.1%
EPS Growth (YoY)Latest quarter vs prior year+90.5%+3.6%+37.0%-19.5%+63.1%+18.2%
KO leads this category, winning 4 of 6 comparable metrics.

Valuation Metrics

OPCH leads this category, winning 3 of 6 comparable metrics.

At 16.3x trailing earnings, OPCH trades at a 78% valuation discount to CVS's 73.4x P/E. On an enterprise value basis, OPCH's 7.4x EV/EBITDA is more attractive than KO's 26.4x.

MetricTOI logoTOIThe Oncology Inst…OPCH logoOPCHOption Care Healt…MCK logoMCKMcKesson Corporat…CAH logoCAHCardinal Health, …CVS logoCVSCVS Health Corpor…KO logoKOThe Coca-Cola Com…
Market CapShares × price$5.4B$3.2B$94.2B$52.7B$130.1B$355.6B
Enterprise ValueMkt cap + debt − cash$5.5B$3.0B$98.9B$58.1B$215.2B$390.8B
Trailing P/EPrice ÷ TTM EPS-9.83x16.35x20.43x34.71x73.35x27.18x
Forward P/EPrice ÷ next-FY EPS est.11.31x17.72x20.79x13.78x25.27x
PEG RatioP/E ÷ EPS growth rate2.43x
EV / EBITDAEnterprise value multiple7.38x13.77x18.97x14.35x26.39x
Price / SalesMarket cap ÷ Revenue10.75x0.57x0.23x0.24x0.32x7.42x
Price / BookPrice ÷ Book value/share2.56x1.72x10.40x
Price / FCFMarket cap ÷ FCF12.57x16.48x28.47x16.66x67.15x
OPCH leads this category, winning 3 of 6 comparable metrics.

Profitability & Efficiency

Evenly matched — MCK and KO each lead in 3 of 9 comparable metrics.

KO delivers a 41.1% return on equity — every $100 of shareholder capital generates $41 in annual profit, vs $4 for CVS. CVS carries lower financial leverage with a 1.24x debt-to-equity ratio, signaling a more conservative balance sheet compared to KO's 1.33x. On the Piotroski fundamental quality scale (0–9), MCK scores 7/9 vs TOI's 4/9, reflecting strong financial health.

MetricTOI logoTOIThe Oncology Inst…OPCH logoOPCHOption Care Healt…MCK logoMCKMcKesson Corporat…CAH logoCAHCardinal Health, …CVS logoCVSCVS Health Corpor…KO logoKOThe Coca-Cola Com…
ROE (TTM)Return on equity+15.3%+3.9%+41.1%
ROA (TTM)Return on assets-26.5%+6.0%+5.7%+2.8%+1.1%+13.1%
ROICReturn on invested capital-41.2%+15.3%+2.5%+33.8%+5.0%+15.8%
ROCEReturn on capital employed-33.7%+12.8%+44.8%+19.2%+6.1%+17.3%
Piotroski ScoreFundamental quality 0–9457657
Debt / EquityFinancial leverage1.24x1.33x
Net DebtTotal debt minus cash$70M-$233M$4.6B$5.5B$85.1B$35.2B
Cash & Equiv.Liquid assets$34M$233M$4.0B$3.9B$8.5B$10.3B
Total DebtShort + long-term debt$104M$0$8.6B$9.3B$93.6B$45.5B
Interest CoverageEBIT ÷ Interest expense-4.96x5.50x51.78x6.38x2.11x10.70x
Evenly matched — MCK and KO each lead in 3 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

TOI leads this category, winning 4 of 6 comparable metrics.

A $10,000 investment in MCK five years ago would be worth $41,299 today (with dividends reinvested), compared to $5,257 for TOI. Over the past 12 months, TOI leads with a +100.4% total return vs OPCH's -34.9%. The 3-year compound annual growth rate (CAGR) favors TOI at 111.1% vs OPCH's -11.6% — a key indicator of consistent wealth creation.

MetricTOI logoTOIThe Oncology Inst…OPCH logoOPCHOption Care Healt…MCK logoMCKMcKesson Corporat…CAH logoCAHCardinal Health, …CVS logoCVSCVS Health Corpor…KO logoKOThe Coca-Cola Com…
YTD ReturnYear-to-date+44.7%-35.6%-4.6%+9.3%+28.9%+20.3%
1-Year ReturnPast 12 months+100.4%-34.9%+7.7%+40.7%+57.7%+17.2%
3-Year ReturnCumulative with dividends+841.3%-30.9%+100.5%+163.7%+53.6%+47.0%
5-Year ReturnCumulative with dividends-47.4%+1.1%+313.0%+300.9%+35.0%+65.6%
10-Year ReturnCumulative with dividends-45.3%+127.6%+337.8%+211.1%+29.5%+121.1%
CAGR (3Y)Annualised 3-year return+111.1%-11.6%+26.1%+38.2%+15.4%+13.7%
TOI leads this category, winning 4 of 6 comparable metrics.

Risk & Volatility

Evenly matched — CVS and KO each lead in 1 of 2 comparable metrics.

KO is the less volatile stock with a -0.20 beta — it tends to amplify market swings less than TOI's 1.95 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CVS currently trades 99.2% from its 52-week high vs OPCH's 56.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricTOI logoTOIThe Oncology Inst…OPCH logoOPCHOption Care Healt…MCK logoMCKMcKesson Corporat…CAH logoCAHCardinal Health, …CVS logoCVSCVS Health Corpor…KO logoKOThe Coca-Cola Com…
Beta (5Y)Sensitivity to S&P 5001.95x0.29x-0.10x-0.07x0.19x-0.20x
52-Week HighHighest price in past year$5.58$36.80$999.00$233.60$102.77$84.04
52-Week LowLowest price in past year$2.02$18.01$637.00$137.75$58.50$65.35
% of 52W HighCurrent price vs 52-week peak+95.2%+56.4%+78.5%+95.8%+99.2%+98.3%
RSI (14)Momentum oscillator 0–10065.344.155.574.472.660.6
Avg Volume (50D)Average daily shares traded1.6M3.2M879K1.9M7.6M12.7M
Evenly matched — CVS and KO each lead in 1 of 2 comparable metrics.

Analyst Outlook

Evenly matched — CVS and KO each lead in 1 of 2 comparable metrics.

Analyst consensus: TOI as "Buy", OPCH as "Buy", MCK as "Buy", CAH as "Buy", CVS as "Buy", KO as "Buy". Consensus price targets imply 50.7% upside for TOI (target: $8) vs 1.6% for CVS (target: $104). For income investors, CVS offers the higher dividend yield at 2.62% vs MCK's 0.39%.

MetricTOI logoTOIThe Oncology Inst…OPCH logoOPCHOption Care Healt…MCK logoMCKMcKesson Corporat…CAH logoCAHCardinal Health, …CVS logoCVSCVS Health Corpor…KO logoKOThe Coca-Cola Com…
Analyst RatingConsensus buy/hold/sellBuyBuyBuyBuyBuyBuy
Price TargetConsensus 12-month target$8.00$31.22$994.86$253.38$103.64$86.13
# AnalystsCovering analysts51431334148
Dividend YieldAnnual dividend ÷ price+0.4%+0.9%+2.6%+2.5%
Dividend StreakConsecutive years of raises11840056
Dividend / ShareAnnual DPS$3.07$2.04$2.67$2.04
Buyback YieldShare repurchases ÷ mkt cap0.0%+9.5%+5.0%+1.5%0.0%+0.2%
Evenly matched — CVS and KO each lead in 1 of 2 comparable metrics.
Key Takeaway

KO leads in 1 of 6 categories (Income & Cash Flow). OPCH leads in 1 (Valuation Metrics). 3 tied.

Best OverallThe Oncology Institute, Inc. (TOI)Leads 1 of 6 categories
Loading custom metrics...

TOI vs OPCH vs MCK vs CAH vs CVS vs KO: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is TOI or OPCH or MCK or CAH or CVS or KO a better buy right now?

For growth investors, The Oncology Institute, Inc.

(TOI) is the stronger pick with 27. 8% revenue growth year-over-year, versus -1. 9% for Cardinal Health, Inc. (CAH). Option Care Health, Inc. (OPCH) offers the better valuation at 16. 3x trailing P/E (11. 3x forward), making it the more compelling value choice. Analysts rate The Oncology Institute, Inc. (TOI) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — TOI or OPCH or MCK or CAH or CVS or KO?

On trailing P/E, Option Care Health, Inc.

(OPCH) is the cheapest at 16. 3x versus CVS Health Corporation at 73. 4x. On forward P/E, Option Care Health, Inc. is actually cheaper at 11. 3x.

03

Which is the better long-term investment — TOI or OPCH or MCK or CAH or CVS or KO?

Over the past 5 years, McKesson Corporation (MCK) delivered a total return of +313.

0%, compared to -47. 4% for The Oncology Institute, Inc. (TOI). Over 10 years, the gap is even starker: MCK returned +337. 8% versus TOI's -45. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — TOI or OPCH or MCK or CAH or CVS or KO?

By beta (market sensitivity over 5 years), The Coca-Cola Company (KO) is the lower-risk stock at -0.

20β versus The Oncology Institute, Inc. 's 1. 95β — meaning TOI is approximately -1074% more volatile than KO relative to the S&P 500. On balance sheet safety, CVS Health Corporation (CVS) carries a lower debt/equity ratio of 124% versus 133% for The Coca-Cola Company — giving it more financial flexibility in a downturn.

05

Which is growing faster — TOI or OPCH or MCK or CAH or CVS or KO?

By revenue growth (latest reported year), The Oncology Institute, Inc.

(TOI) is pulling ahead at 27. 8% versus -1. 9% for Cardinal Health, Inc. (CAH). On earnings-per-share growth, the picture is similar: Cardinal Health, Inc. grew EPS 87. 0% year-over-year, compared to -62. 0% for CVS Health Corporation. Over a 3-year CAGR, TOI leads at 25. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — TOI or OPCH or MCK or CAH or CVS or KO?

The Coca-Cola Company (KO) is the more profitable company, earning 27.

3% net margin versus -12. 1% for The Oncology Institute, Inc. — meaning it keeps 27. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: KO leads at 28. 7% versus -7. 2% for TOI. At the gross margin level — before operating expenses — KO leads at 61. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is TOI or OPCH or MCK or CAH or CVS or KO more undervalued right now?

On forward earnings alone, Option Care Health, Inc.

(OPCH) trades at 11. 3x forward P/E versus 25. 3x for The Coca-Cola Company — 14. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for TOI: 50. 7% to $8. 00.

08

Which pays a better dividend — TOI or OPCH or MCK or CAH or CVS or KO?

In this comparison, CVS (2.

6% yield), KO (2. 5% yield), CAH (0. 9% yield), MCK (0. 4% yield) pay a dividend. TOI, OPCH do not pay a meaningful dividend and should not be held primarily for income.

09

Is TOI or OPCH or MCK or CAH or CVS or KO better for a retirement portfolio?

For long-horizon retirement investors, The Coca-Cola Company (KO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0.

20), 2. 5% yield, +121. 1% 10Y return). The Oncology Institute, Inc. (TOI) carries a higher beta of 1. 95 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (KO: +121. 1%, TOI: -45. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between TOI and OPCH and MCK and CAH and CVS and KO?

These companies operate in different sectors (TOI (Healthcare) and OPCH (Healthcare) and MCK (Healthcare) and CAH (Healthcare) and CVS (Healthcare) and KO (Consumer Defensive)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: TOI is a small-cap high-growth stock; OPCH is a small-cap deep-value stock; MCK is a mid-cap quality compounder stock; CAH is a mid-cap quality compounder stock; CVS is a mid-cap quality compounder stock; KO is a large-cap quality compounder stock. CAH, CVS, KO pay a dividend while TOI, OPCH, MCK do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.